Eli Lilly Plans to Acquire Psychedelic Drug Company Atai/Beckley
Miles Bennett
Eli Lilly is negotiating to acquire psychedelic-drug company AtaiBeckley at a premium to its ~$2 billion market cap; a deal would mark the biggest move yet by a major pharma into the psychedelics space.
What is Lilly actually buying?
AtaiBeckley's core asset is BPL-003 — a fast-acting nasal spray targeting treatment-resistant depression and social anxiety.
This means → Lilly is not buying a company so much as the most advanced psychedelic drug pipeline near market.
BPL-003 holds an FDA "Breakthrough Therapy" designation. Mid-stage trials showed significant symptom relief within two days of a single dose, lasting up to eight weeks.
What makes it better than rivals?
BPL-003's psychedelic experience lasts roughly one to two hours — far shorter than Compass Pathways' candidate, which can require up to eight hours of patient monitoring.
In plain terms = a patient sits for an hour or two, not a full day — and the clinic can treat more patients per session.
CEO Srinivas Rao said the goal is a product that plugs directly into J&J's existing Spravato care model. This means → no new infrastructure needed, and a shorter path to commercialization.
Why is Lilly moving into psychedelics?
Lilly transformed depression treatment three decades ago with Prozac and has since invested heavily in Alzheimer's and non-addictive pain therapies.
This reflects a long neuroscience track record — psychedelics are a natural extension of that line, not a leap into the unknown.
People familiar with the matter say Lilly has been watching the psychedelics space for some time; this deal is not a snap decision.
How big is this market, and who else is in it?
Bloomberg Intelligence estimates the psychedelic-therapy market could reach $7 billion in sales by 2032.
J&J's Spravato already has first-mover status; AbbVie and Definium Therapeutics are building pipelines too.
This means → Lilly is not the first mover, but acquiring AtaiBeckley would give it a candidate with the most advanced clinical data and the shortest treatment session — a strong hand in the commercialization race.
Content is for reference only, not financial advice.